Can a sedative calm the Body's stress response during brain tumor surgery?

NCT ID NCT05005715

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving the sedative dexmedetomidine during pituitary tumor surgery can dampen the body's stress response and improve early recovery. About 64 adults with non-functioning pituitary adenomas undergoing endoscopic transsphenoidal surgery will be randomly assigned to receive either dexmedetomidine or a placebo (saline) intravenously during the procedure. Researchers will measure recovery quality using a standard questionnaire and track hormone levels related to stress.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dexmedetomidine, a sedative drug given intravenously during surgery
What this could lead to
If it works, this could point toward a way to help patients recover more comfortably after pituitary tumor surgery.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. Dexmedetomidine can cause low blood pressure or slow heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

64 people

The number who actually took part.

Started

Aug 2021

Finished

Apr 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non-functioning patients undergoing endoscopic transsphenoidal tumor surgery under general anesthesia Exclusion Criteria: * Patients who do not agree to participate in the study * Patients with contraindication to dexmedetomidine * Patients with previous history of endoscopic transsphenoidal tumor surgery * Patients who take anticoagulants or have bleeding disorder * Patients with conduction block or cardiovascular disease * Patients with psychiatric disease such as dementia, delirium * Patients have difficulty filling out the QoR-15 questionnaire * Pregnant or lactating women * Patients who have allergies to propofol, remifentanil, fentanyl or rocuronium * Patients with myasthenia gravis or myasthenic syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-functioning pituitary adenoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seoul National University Hospital

    Seoul, Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.